Top pharmaceutical companies manufacturing DyMista include Meda Pharmaceuticals, which is part of the publicly traded company Aptalis Pharma AB [1]. DyMista is an intranasal corticosteroid spray used for the treatment of allergic rhinitis [2].
When does DyMista patent expire?
The patent for DyMista, specifically US Patent No. 8,500,001, was set to expire in 2025 [3]. However, patent litigation can impact these dates. DrugPatentWatch.com tracks patent statuses and potential challenges [4].
What are the active ingredients in DyMista?
DyMista is a combination medication containing two active pharmaceutical ingredients: fluticasone propionate and azelastine hydrochloride [2]. Fluticasone propionate is a corticosteroid, and azelastine hydrochloride is an antihistamine.
How does DyMista work?
DyMista combines the anti-inflammatory effects of fluticasone propionate with the antihistamine action of azelastine hydrochloride. Fluticasone propionate reduces inflammation in the nasal passages, while azelastine hydrochloride blocks the action of histamine, a substance the body produces during an allergic reaction that causes symptoms like sneezing and runny nose [2].
What are the alternatives to DyMista?
Alternatives for allergic rhinitis treatment include other intranasal corticosteroid sprays, oral antihistamines, decongestants, and leukotriene modifiers. The choice of treatment depends on the severity and type of symptoms, as well as individual patient factors [5].
Who are DyMista's main competitors?
Competitors in the allergic rhinitis market include other intranasal corticosteroid products like Flonase (fluticasone propionate), Nasonex (mometasone furoate), and Rhinocort (budesonide). Combination therapies also compete with DyMista [5].
Can generic versions of DyMista be made?
The availability of generic versions of DyMista is dependent on the expiry of its patents and any ongoing litigation. Once patent protection lapses, other companies may be able to develop and market generic equivalents, provided they meet regulatory approval [3][4].
What are the side effects of DyMista?
Common side effects associated with DyMista can include nosebleeds, unpleasant taste and smell, and nasal irritation [6]. As with any medication, patients should discuss potential side effects with their healthcare provider.
What is the FDA approval status for DyMista?
DyMista, under the brand name Dymista, received FDA approval for the treatment of allergic rhinitis [7].
Where can I find more information on drug patents?
DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and potential legal challenges, which can be a valuable resource for understanding the market landscape for medications like DyMista [4].
Sources:
1. https://www.drugpatentwatch.com/companies/apta
2. https://www.drugpatentwatch.com/drug/dymista
3. https://www.drugpatentwatch.com/drug/fluticasone-azelastine-nasal
4. https://www.drugpatentwatch.com/
5. https://www.uptodate.com/contents/allergic-rhinitis-epidemiology-pathogenesis-and-triggers
6. https://www.drugs.com/sfx/dymista-side-effects.html
7. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ProcessSearch.process&Appl_No=205275